Centene‘s stock has experienced a significant decline—more than 42% in the past six months—primarily due to the withdrawal of its 2025 financial guidance following some troubling developments in its core health insurance business.
Centene’s recent stock drop is closely linked to a combination of higher-than-expected medical costs amid challenging trends in the Affordable Care Act (ACA) market and anticipation of the scheduled end to enhanced ACA subsidies at the end of 2025. While shares jumped earlier this week after Centene affirmed its guidance, which was higher than analysts’ estimates, it faces an uncertain road ahead.
